ScinoPharm Taiwan (1789) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT
5.6B, trading at NT
9.75 on the TAI. This SniperIQ fundamentals page covers ScinoPharm Taiwan's valuation (P/E 153.7x, P/B 1.6x), profitability (net margin 3.4%), revenue (NT
.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
5.6B
P/E (TTM)153.7x
Net Margin3.4%
Revenue (FY25)NT
.2B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is ScinoPharm Taiwan's market cap?
ScinoPharm Taiwan (1789) has a market capitalization of approximately NT
5.6B, trading at NT
9.75 on the TAI. Market cap moves with the live share price.
What is ScinoPharm Taiwan's P/E ratio?
ScinoPharm Taiwan's trailing twelve-month P/E ratio is 153.7x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ScinoPharm Taiwan?
ScinoPharm Taiwan runs a net profit margin of 3.4%, a gross margin of 33.9%, and an operating margin of 2.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ScinoPharm Taiwan generate?
ScinoPharm Taiwan reported revenue of NT
.2B for fiscal year 2025, with net income of NT
37M and earnings per share (EPS) of 0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ScinoPharm Taiwan pay a dividend?
ScinoPharm Taiwan offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is ScinoPharm Taiwan financially healthy?
ScinoPharm Taiwan carries a debt-to-equity ratio of 0.08x and a current ratio of 6.55x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ScinoPharm Taiwan a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ScinoPharm Taiwan (1789) the key facts are: market cap NT
5.6B, P/E 153.7x, revenue NT
.2B, 52-week range 16.55-29.1. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ScinoPharm Taiwan's full fundamentals live
Get ScinoPharm Taiwan's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.